SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective
treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses …

We report a lymphoma patient with profound B-cell deficiency after chemotherapy combined
with anti-CD20 antibody successfully treated with remdesivir and convalescent plasma for …

Background The severity of COVID-19 is associated with an elevated level of a variety of
inflammatory mediators. Increasing evidence suggests that the Th17 response contributes to …

Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Introduction Spain was one of the most affected countries during the first wave of COVID-19,
having the highest mortality rate in Europe. The aim of this retrospective study is to estimate …

The aim of this study is to describe the features, the outcomes, and the clinical issues related
to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized …

Objectives This study investigated remdesivir's clinical use to provide direct evidence of
effectiveness for a low-middle income Asian setting. Design A one-to-one propensity score …

Background Remdesivir is a prodrug of the nucleoside analogue GS-441524 and is under
evaluation for treatment of SARS-CoV-2-infected patients. Objectives To evaluate the …

BACKGROUND Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …

Results: Out of the 160 COVID-19 patients, 32 were moderately ill (males: 29, females: 03)
and were treated with remdesivir along with steroids and low molecular weight heparin …